A Study of Fruquintinib in Adults With Metastatic Colorectal Cancer in Poland (NCT07623174) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
A Study of Fruquintinib in Adults With Metastatic Colorectal Cancer in Poland
110 participantsStarted 2026-07-31
Plain-language summary
Metastatic colorectal cancer or mCRC is a cancer that starts in the parts of the large intestine (the colon or rectum) and has already spread to other parts of the body. This cancer can be hard to treat because it can behave differently from one person to another. Over time, treatments may stop working, and side effects can build up. In later treatment stages, there are only a few standard medicine options available. Because of this, studies often look at both how long people live and how treatment affects quality of life.
The main aim of this study is to see how long adults in Poland with mCRC live without their cancer getting worse (progression-free survival or PFS) when they receive fruquintinib after at least two previous treatments. Fruquintinib (TAK 113) is a medicine taken by mouth that is designed to slow tumor growth.
Other aim is to find out how long adults in Poland with mCRC live while being treated with fruquintinib (overall survival or OS). The study also wants to record how fruquintinib is used in routine care in adults with mCRC in Poland (for example when treatment starts, changes in doses, and how long treatment continues). Another aim is to learn about people with mCRC, such as their medical history and past treatment as well as their quality of life while they are in the study.
The study will look at data already existing in the participants' medical charts.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Adult participants (aged 18 years and older) with mCRC who are eligible for treatment with fruquintinib under the national drug program B.4 and will receive fruquintinib as third or subsequent line treatment after progression on or intolerance to trifluride/tipiracil.
. Participants who signed informed consent to participate in the study at the time of enrollment and prior to the fruquintinib treatment initiation.
. Participants for whom adequate medical records are available to support the data collection requirements.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial is listed as 'not yet recruiting' in Poland — do you know when it's expected to open, and would waiting for it affect my current treatment options or disease progression?
2The main thing this trial is measuring is progression-free survival — can you help me understand what that means in practical terms for my situation, and how fruquintinib's effect on it might compare to what standard treatments could offer me right now?
3Since this trial doesn't have a listed phase, what does that tell us about how much is already known about fruquintinib's safety and effectiveness in metastatic colorectal cancer, and are there completed studies we should look at together?
4Given that this study is based in Poland, what would the logistics actually look like for me — travel, how often I'd need to be seen, and whether my care here at home could continue alongside it?
5Are there other treatment paths or trials that are already open and enrolling that you think I should consider before committing to waiting for this one to start?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.